Click HERE to watch the video and answer the questions below to submit for CPD points 1.Which of the below statements regarding the Women’s Health Initiative (WHI) study are correct? a. Negative outcomes of the WHI study had a negative impact on the use of hormone therapy globally b. The study raised concerns that breast cancer may be linked to hormone therapy c. The study raised concerns about increased cardiovascular risk in women taking hormone therapy d. The concerns raised in the WHI study were positively linked to conjugated equine estrogen (CEE) in combination with medroxyprogesterone acetate (MPA) e. All of the above 2.Which TWO of the hormones listed below have the same chemical and molecular structure as the hormones produced naturally in a woman’s body? Ethinyl estradiol Estradiol Conjugated equine estrogen (CEE) Progesterone (P4) Levonorgestrel A. 1 and 4 B. 2 and 4 C. 1 and 3 D. 1 and 5 E. 3 and 4 3.Which of the below were the co-primary efficacy endpoints for the REPLENISH study? Reduction in the frequency of vasomotor symptoms at weeks 4 and 12 Reduction in the severity of vasomotor symptoms at weeks 4 and 12 Endometrial safety over 52 weeks Thrombo-embolic adverse events over 52 weeks Bleeding profile over 52 weeks A. 1 and 2 B. 2 and 4 C. 1 and 3 D. 1 and 5 E. 3 and 4 4. Choose the correct option to complete the sentence: Estradiol/progesterone (E2/P4) demonstrated statistically significant reductions in the frequency and severity of …………………………….vs. placebo at week 4 and 12. a. Vasomotor symptoms b. Mood swings 5. Which one of the below is NOT one of the four domains of the Menopause Specific Quality of Life (MENQOL score) assessed in the REPLENISH study? a. Neurological b. Vasomotor c. Psychosocial d. Physical e. Sexual 6. True or false: In the REPLENISH study, 100 mg of progesterone (P4) in combination with 1 mg of estradiol (E4) successfully prevented endometrial hyperplasia a. True b. False 7. Which percentage of women did not report any episode of bleeding or spotting at year 1? a. 85.4% b. 79.3 % c. 90.2 % d. 63.7% e. 98.6% 8. Which of the following statements about the mammogram results from the REPLENISH study are correct? a. The incidence of abnormal mammograms in the estradiol/progesterone (E2/P4) group was 3.1 % b. The incidence of abnormal mammograms in the E2/P4 group was consistent with the incidence seen for placebo c. E2/P4 was not associated with increased mammographic breast density d. The incidence of abnormal mammograms for E2/P4 in the REPLENISH study was much lower than that reported for conjugated equine estrogen/medroxyprogesterone acetate (CEE/MPA) in the Women’s Health Initiative (WHI) study e. All of the above 9. Which of the following statements about the effect of estradiol/progesterone (E2/P4) on coagulation parameters after 1 year is correct? a. E2/P4 significantly increased activated partial thromboplastin b. E2/P4 significantly increased prothrombin c. E2/P4 significantly decreased Protein S d. E2/P4 showed a clinically meaningful decrease in antithrombin activity e. E2/P4 was NOT associated with clinically meaningful changes on coagulation parameters 10. Which of the following statements about the effect of estradiol/progesterone (E2/P4) on cardiometabolic parameters is INCORRECT? a. E2/P4 significantly increased HDL-cholesterol b. E2/P4 is liver neutral, which explains its lack of clinically meaningful changes in lipid parameters c. E2/P4 was not associated with any meaningful changes in glucose parameters d. E2/P4 had no clinically meaningful impact on weight e. E2/P4 was not associated with any clinically meaningful changes in blood pressure Name: Surname: MP number: Practice No: Email address: Contact telephone number:
